All News

Abst1783 #ACR21 #ACRBest @RheumNow Canadian study reports promising trends on hospitalizations for serious infections in PsA: 2012 – 2017 statist signif ⬇️ in discharges for sepsis, skin & soft tissue infect & UTI (p < 0.001 for all). no statistical difference in the trend of PNA https://t.co/lqtCzUFPAW
Olga Petryna DrPetryna ( View Tweet)
We may be getting a new urate lowering therapy. Tigulixostat is a non-purine selective xanthine oxidase inhibitor. Nothing worrying on safety. But I think febuxostat is probably more effective than this? Abstr#L05 #ACR21 @RheumNow https://t.co/Lg0slMlah2
Richard Conway RichardPAConway ( View Tweet)
Upadacitinib showed similar efficacy in AS pts compared to PsA pts with axial involvement ⭐️PsA pt w/ axial involvement and AS pts with differences in baseline characteristics #ACR21 @RheumNow Abs#1802 https://t.co/QvyayelBYU https://t.co/50dNQm30vf

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
How do RA pts go with ICI cancer therapy? @VUMCRheum audit reflects overall prev experience: - approx 50% flare (?some reflect DMARD W/H) - flares overwhelmingly managable - few (1/19 here) cease ICI due to RA flare RA pts deserve best cancer Rx too!! #ACR21 ABST1523 @RheumNow

David Liew drdavidliew ( View Tweet)

Advantages of treat to target (of serum urate) beyond less gout flares? Maybe equal to ⬇️MACE events - I hope in long term less MACE due to less ⬆️CRP w flares. Modelling observational study abst#L06 #ACR21 #ACRBest @RheumNow below is comparative safety T2T better than usual care https://t.co/95M6lNX416
Janet Pope Janetbirdope ( View Tweet)
Dr. Despotovic shares general principles about ICU admissions in patients w/ #rheumatic disease. 🔺#SLE, RA, systemic #vasculitis, SSc, IIMs 🔺serologic testing useful but interpret w/n clinical context @RheumNow #ACR21 https://t.co/jb3Mt31dZz
sheila RHEUMarampa ( View Tweet)
Abst1625 #ACR21 @RheumNow study of kids w/covid induced MIS-C: 91% w/shock & GI ax, conjunctivitis & mucocutaneous involvement. ⬆️CRP,D-Dimer, Troponin, &BNP. On ECHO, 36% had myocardial dysfunction &27% coronary artery abnormalities. 64% required ICU admiss. Rx IVIG& steroids

Olga Petryna DrPetryna ( View Tweet)

#ACR21 Thieves! TM11. Belly pain in patient with RA nodules: ⭐️ A: rheumatoid nodulosis of pancreas and duodenum. Great case! @Rheumnow https://t.co/PuO4tka3FJ
Eric Dein ericdeinmd ( View Tweet)
Excellent overview on assessment of patients with #PsA by @AlexisOgdie! Really clear and easy-to-follow slides to add structure to clinical assessment. #ACR21 @RheumNow https://t.co/XGZrCxOukm
Mrinalini Dey DrMiniDey ( View Tweet)
Sub-analysis of ICHIBAN study looking at adverse events in tocilizumab treated patients with/without steroids. Steroids associated with small increase in adverse events across board. Abstr#1693 #ACR21 @RheumNow https://t.co/ldiovirKpo
Richard Conway RichardPAConway ( View Tweet)
What is the effect of #avacopan on renal function in pts with #ANCA #vasculitis? 👉🏼Results from ADVOCATE show greater recovery of kidney function with avacopan vs steroids 👉🏼Particularly marked in pts with CKD4 and eGFR<60 Abs#L14 #ACR21 @RheumNow https://t.co/5z7YulxVAj https://t.co/LnJr4gLuTV

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
Fr AQUILA study: #Uveitis status in AS or PsA pts given SEC 👁‍🗨3 pts w/o uveitis at BL developed new onset uveitis during study 👁‍🗨Most pts w/uveitis at BL - status remained unchanged or improved 👁‍🗨SEC did not ⬆ risk of uveitis @RheumNow #ACR21 abs1738 https://t.co/IGUpgXBLvt
sheila RHEUMarampa ( View Tweet)
Abst1632 #ACR21 #ACRBest @RheumNow 25 children w/ uSAID & MEFV mutations: E148Q mutation standouts-32% heterozygous for E148Q, Asian ancestry seen in 37% kids w/ E148Q. E148Q assoc w/longer febrile episodes& less likely to have a full response to colchicine (25% vs 70%; p = 0.03) https://t.co/Rst6KHntPD
Olga Petryna DrPetryna ( View Tweet)
Predictor of PsO transition to PsA? Age - pts dx with PsO at 42 developed PsA 12 years sooner than pts dx at 18 Abs#1798 #ACR21 @RheumNow https://t.co/1zTifI3H1V https://t.co/MVP8VWicyS

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
Abst1773 #ACR21 @rheumnow guselkumab outperforms ustekinumab in both msk & skin domains in bio naive & bio experienced alike- data from pivotal Phase III trials : at weeks 52 GUS better ACR20, PASI100 in both doses vs Stelara https://t.co/lfddaCJA5O
Olga Petryna DrPetryna ( View Tweet)
#ACR21 Thieves: SLE and SSc with worsening cytopenia and hematuria despite treatment: Maria Powell - presents overlap case with PNH, responded to eculizumab @Rheumnow https://t.co/CGvHEMA3lI
Eric Dein ericdeinmd ( View Tweet)
Use your good sun screen/blocker. UV radiation is best blocked! Changes beyond skin damage and cancer. Immune activation. @RheumNow #ACR21 #climate change https://t.co/VyCZR5rt8x

Links:

Janet Pope Janetbirdope ( View Tweet)

Peripheral SpA: Dr. Antoni Chan and Dr. Nelly Ziade Dr. Chan ( @synovialjoints) interviews Dr. Ziade about abstract #1787 presented at the #ACR21 annual meeting. https://t.co/Sdd1HHKRib https://t.co/ynRocjviVu

Links:

Dr. John Cush RheumNow ( View Tweet)
Meta-analysis of PUFA supplementation in RA. Apparent benefits across most measures, albeit often small. Abstr#1682 #ACR21 @RheumNow https://t.co/1rGhpqvJvp
Richard Conway RichardPAConway ( View Tweet)
No benefit to using MTX in combination with ustekinumab in PsA. No difference in efficacy for arthritis, enthesitis, dactylitis, skin, QoL or function. Abstr#L12 #ACR21 @RheumNow https://t.co/iojKLqRb06
Richard Conway RichardPAConway ( View Tweet)
×